The positive results of the phase 2b clinical trial for the TYK2TYK2 inhibitor drug TAK-279 have rendered Takeda's acquisition of the drug from Nimbus Therapeutics a prudent decision
22 Mar 2023
Clinical Study
Preview
Source: SYNAPSE
A few months ago, Takeda paid $4 billion to buy the psoriasis drug TAK-279 from startup Nimbus Therapeutics. Recently, Takeda announces the positive results in Phase 2b study of the drug, at the highest dose of TAK-279, 46% of patients achieved PASI 90 and 33% achieved PASI 100 at 12 Weeks, Indicating a near-total or total clearance of skin lesions. It hasn’t been previously shown with an oral pill and approaches that of more potent injectable drugs.
What is TAK-279?
TAK-279 is one of many medicines in development that target TYK2, an enzyme involved in cell signaling pathways that are implicated in inflammation. These treatments have become highly coveted by drugmakers because of their potential to be oral alternatives to top-selling, injectable medicines like Humira. Last September, the Food and Drug Administration made Sotyku the first TYK2 inhibitorTYK2 inhibitor approved, clearing it for psoriasis.
TAK-279 is a small molecule drug developed by Nimbus Therapeutics LLC that targets TYK2, a member of the Janus kinase (JAK) family involved in the signaling pathways of various cytokines. TAK-279 functions as a TYK2 inhibitorTYK2 inhibitor and is being investigated for its potential therapeutic applications in autoimmune diseases such as plaque psoriasis and psoriasis. This drug aims to interrupt the JAK/STAT signaling pathway, which plays a crucial role in immune cell function and has been implicated in a range of autoimmune diseases. Currently, TAK-279 has reached phase 2 clinical trials, the second highest phase of clinical development. The progress made thus far in developing TAK-279 suggests its potential as a promising therapeutic option for patients with autoimmune diseases.
Preview
Source: SYNAPSE
Preview
Source: SYNAPSE
About Psoriasis
Psoriasis is a chronic, immune-mediated disorder with cutaneous and systemic manifestations and substantial negative effects on patient quality of life. Psoriasis has a strong, albeit polygenic, genetic basis. Whereas approximately half of the accountable genetic effect of psoriasis maps to the major histocompatibility complex, >70 other loci have been identified, many of which implicate nuclear factor-κB, interferon signalling and the IL-23–IL-23 receptor axis.
Search the drug intelligence database: Synapse, a total of 970 drugs and 3509 clinical trials were found for the treatment of psoriasis. For this indication, the top three research and development organizations are Pfizer, Novartis and Amgen, the major R&D targets are focused on TNF-α、GR and LTα. The top three types of drug development for this indication are Small molecule drug, Monoclonal antibody, and Biosimilar.
Preview
Source: SYNAPSE
Finally
Takeda Will Evaluate TAK-279 in Additional Immune-Mediated Diseases Including Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD), and Explore Further Indications in the Future.
If you’re interested in learning more about this space or keeping track of drug development and clinical trials, sign up for Synapse（synapse.patsnap.com）, our freemium product offering.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.